Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Phentermine Hydrochloride,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Medix
Deal Size : Undisclosed
Deal Type : Partnership
KVK Tech’s Lomaira Completes Registration in Mexico Through Partner Medix
Details : Through the partnership, Medix will gain the exclusive rights to manufacture, distribute, and market Lomaira (Phentermine Hydrochloride) in Mexico. It is indicated for the treatment of obesity.
Product Name : Lomaira
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 31, 2024
Lead Product(s) : Phentermine Hydrochloride,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Medix
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Phentermine Hydrochloride,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase IV
Sponsor : Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-term Effectiveness of the Antiobesity Medication Phentermine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2022
Lead Product(s) : Phentermine Hydrochloride,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Sponsor : Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable